Xinnate is a young biopharmaceutical company built on groundbreaking scientific research on innate defence and healing mechanisms – evolutionary biological systems with the purpose of keeping us healthy. One of these innate defence peptides has shown to be an effective ”natural” and unique way of reducing excessive inflammation as well as preventing infection.

Xinnate specializes in the development of proprietary peptide-based drugs for prevention and treatment of inflammation and infection within the areas skin and wounds, surgical materials and biomaterials.

The company was founded in 2019 and is based on 15 years of world class research from Lund University. The first area to be addressed by Xinnate is the rare skin disease Epidermolysis Bullosa.